Brian S. Singer; Jone A. Fishbein; Stefan K. Blino
Abstract
Cervical cancer represents one of the most common malignancies in women worldwide and predominantly affects women of poor socioeconomic status. Persistent infection with high-risk human papilloma virus (HPV) is an essential factor for development of cervical cancer. The advent of functional genomics and proteomicshas provided hope of discovering novel biological markers for use in the screening, early diagnosis, prognostication and prediction of response to therapy. E6 and E7 oncoproteins of HPV have been known to play major roles in malignant transformation of cervical cells. Accumulating evidences have suggested that E6 oncoprotein may also contribute to cervical carcinogenesis through modulating cellular signaling pathways. Multiple mechanisms, including activation of EGFR or inflammatory cell signaling pathway, have been implicated in malignant transformation by HPV. Therefore, targeting E6 may be a rational approach for chemoprevention and treatment of cervical cancer, and understanding its oncogenic processes may help us to design novel therapeutic strategies. In this review, we discussed the roles of E6 oncoprotein in cervical carcinogenesis, altering several cellular signaling pathways involved in cell proliferation, angiogenesis and apoptosis.
Keywords: HPV; E6; Cervical cancer; Oncoprotein
You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use.
References
1. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88:63–73. [PubMed]
2. Muñoz N, Bosch FX, de Sanjosé S, et al. International Agency on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518–527. [PubMed]
3. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002 cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press; 2004. IARC Cancer Base No.5 version 2.0. [Publisher]
4. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621–632. [PubMed]
5. Stone MK, Karem LK, Sternberg RM, et al. Seroprevalence of human papillomavirus type16 infection in the United States. J Infect Dis 2002;186:1396–1402. [PubMed]
6. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-632. [PubMed]
7. Kleter B, van Doorn LJ, Ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human Papillomaviruses. Am J Pathol 1998;153:1731-1739. [PubMed]
8. Tsai TC, Chen SL. The biochemical and biological functions of human papilloma virus type16 E5 protein. Archieves Virology 2003;148:1445-1453. [PubMed]
9. Schmitz M, Driesch C, Beer-Grondke K, Jansen L, Runnebaum IB, Durst M. Loss of gene function as a consequence of human papillomavirus DNA integration. Int J Cancer 2012;131:E593–602. [PubMed]
10. de Villiers EM. Human pathogenic papillomavirus types: an update. Curr Top Microbiol Immunol1994;186:1-12. [PubMed]
11. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science 2006;110:525-541. [PubMed]
12. Microbiology and molecular biology reviews. 2004. pp.1092–2172.
13. Gao P, Zheng J. High-risk HPV E5- induced cell fusion a critical initiating event in the early stage of HPV-associated cervical cancer. J Virol 2010;7:238. [PubMed]
14. Nariseuva Saito M. et al. Basic mechanisms of High-risk human papilloma virus induced carcinogenesis. Cancer Science 2007; 98:1505–1511. [PubMed]
15. Tsai TC, Chen SL. The biochemical and biological functions of human papilloma virus type16 E5 protein. Archieves Virology 2003;148:1445–1453. [PubMed]
16. Zerfass K, Schulze A, Spitkovsky D, Friedman V, Henglein B, Jansen-Dürr P. Sequential activation of cyclin E and cyclin A gene expression by human papilloma virus type 16E7 through sequences necessary for transformation. J Virol 1995; 69:6389–6399. [PubMed]
17. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22(38):5938-5945. [PubMed]
18. Au Yeung CL, Tsang TY, Yau PL, Kwok TT. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene 2011; 30(21):2401-2410. [PubMed]
19. Wang X, Wang HK, McCoy JP, et al. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 2009; 15(4):637-647. [PubMed]
20. Chen CL, Hsieh FC, Lieblein JC, et al. Stat3 activation in human endometrial and cervical cancers. Br J Cancer 2007; 96(4):591-99. [PubMed]
21. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008; 3(7):e2557. [PubMed]
22. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92(9):690-698. [PubMed]
23. Androphy EJ, Hubbert NL, Schiller JT, Lowy DR. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J 1987; 6(4):989-992. [PubMed]
24. Schmitz M, Driesch C, Beer-Grondke K, Jansen L, Runnebaum IB, Durst M. Loss of gene function as a consequence of human papillomavirus DNA integration. Int J Cancer 2012;131:E593–602. [PubMed]
25. Gupta S, Takhar PP, Degenkolbe R, et al. The human papillomavirus type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1. Virology 2003; 317(1):155–64. [PubMed]
26. Kelley ML, Keiger KE, Lee CJ, Huibregtse JM. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J. Virol 2005;79(6): 3737-47. [PubMed]
27. Glaunsinger BA, Lee SS, Thomas M, Banks L, Javier R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 2000;19(46):5270–80. [PubMed]
28. White EA, Kramera RE, Tan AM. Comprehensive analysis of host cellular interactions with Human Papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J. Virol 2012; 86(24):13174-13186. [PubMed]
29. Vos RM, Altreuter J, White EA, Howley PM. The ubiquitin-specific peptidase usp15 regulates human papilloma virus type 16 e6 protein stability. J. Virol 2009;83(17):8885-8892. [PubMed]
30. Boulet G, Horvath C, Broeck DV, Sahebali S, Bogers J. The International Journal of Biochemistry & Cell Biology 2007; 39:2006-2011. [PubMed]
31. Szarewski A. Prophylactic HPV vaccines. Eur J Gynaecol Oncol 2007;28:165-169. [PubMed]
32. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-1136. [PubMed]
33. Lacey CJ, Thompson HS, Monteiro EF, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179:612-618. [PubMed]
34. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USAm 2000;97:12513-12518. [PubMed]
35. Hamada K, Sakaue M, Alemany R, et al. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol 1996;63:219-227. [PubMed]
36. Lagrange M, Charbonnier S, Orfanoudakis G, et al. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6. J Gen Virol 2005; 86:1001–1007. [PubMed]
37. Giovane C, Trave G, Briones A, Lutz Y, Wasylyk B, Weiss E. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53. J Mol Recognit 1999;12:141-152. [PubMed]
38. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 2000; 97:6693-6697. [PubMed]
